Advanced in Esophageal Cancer

Michael K. Stahl

Kliniken Essen Mitte
Essen, NW, DE 
Advanced in Esophageal Cancer
Kliniken Essen Mitte
Essen, NW, DE 
OverviewLocationsClinical Research

Overview

Michael Stahl practices in Essen, Germany. Mr. Stahl is rated as an Advanced expert by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Esophageal Cancer, Stomach Cancer, Pancreatic Cancer, and Colorectal Cancer.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 24 articles in the study of Esophageal Cancer.

Gender
Male

Locations

Kliniken Essen Mitte
Essen, NW 45136, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab, Pertuzumab
Study Phase: Phase 2
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Enrollment Status: Terminated
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: Aspirin
Study Phase: Phase 3
Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
Enrollment Status: Active_not_recruiting
Publish Date: January 05, 2024
Intervention Type: Drug, Other
Study Drug: Nivolumab+Ipilimumab
Study Phase: Phase 2
View 2 Less Clinical Trials

53 Total Publications

Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy.
Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 13, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Stahl's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile